PLoS ONE (Jan 2015)

Influence of Pneumococcal Conjugate Vaccine on Acute Otitis Media with Severe Middle Ear Inflammation: A Retrospective Multicenter Study.

  • Hirotoshi Sugino,
  • Shigeru Tsumura,
  • Masaru Kunimoto,
  • Masuhiro Noda,
  • Daisuke Chikuie,
  • Chieko Noda,
  • Mariko Yamashita,
  • Hiroshi Watanabe,
  • Hidemasa Ishii,
  • Toru Tashiro,
  • Kazuhiro Iwata,
  • Takashi Kono,
  • Kaoru Tsumura,
  • Takahiro Sumiya,
  • Sachio Takeno,
  • Katsuhiro Hirakawa

DOI
https://doi.org/10.1371/journal.pone.0137546
Journal volume & issue
Vol. 10, no. 9
p. e0137546

Abstract

Read online

The Japanese guidelines for acute otitis media in children recommend classifying acute otitis media by age, manifestations and local findings, and also recommend myringotomy for moderate-grade cases with severe local findings, severe-grade cases, and treatment-resistant cases. The heptavalent pneumococcal conjugate vaccine was released in Japan in February 2010. In Hiroshima City, public funding allowing free inoculation with this vaccine was initiated from January 2011, and the number of vaccinated individuals has since increased dramatically. This study investigated changes in the number of myringotomies performed to treat acute otitis media during the 5-year period from January 2008 to December 2012 at two hospitals and five clinics in the Asa Area of Hiroshima City, Japan. A total of 3,165 myringotomies for acute otitis media were performed. The rate of procedures per child-year performed in <5-year-old children decreased by 29.1% in 2011 and by 25.2% in 2012 compared to the mean rate performed in the 3 years prior to the introduction of public funding. A total of 895 myringotomies were performed for 1-year-old infants. The rate of myringotomies per child-year performed for acute otitis media in 1-year-old infants decreased significantly in the 2 years after the introduction of public funding for heptavalent pneumococcal conjugate vaccine compared to all years before introduction (p<0.000001). Our results suggest a benefit of heptavalent pneumococcal conjugate vaccine for acute otitis media in reducing the financial burden of myringotomy. In addition, this vaccine may help prevent acute otitis media with severe middle ear inflammation in 1-year-old infants.